Skip to main content
Explore URMC

Michael C. Keefer, M.D.

Contact Information

Phone Numbers

Office: (585) 275-5871

Fax: (585) 442-9328

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting

Infectious Diseases



Dr. Keefer has over 18 years of experience in the preventive HIV vaccine field, having served as Director of the University of Rochester's NIH-supported HIV Vaccine Trials Unit (HVTU) since 1991. Working initially as a laboratory investigator he was the first to demonstrate T-cell mediated immune responses to a candidate HIV vaccine. Subsequently he focused his attention on the design and conduct of clinical trials. When the HIV Vaccine Trials Network (HVTN) expanded to include international sites in 1999, he assumed the position of the HVTN's Associate Director of Scientific Administration. In that role his duties include leadership of scientific and administrative committees and visits to international sites. Dr Keefer is also PI of an NIH-funded Program Project entitled "HSV-1 amplicon vectors for HIV vaccine delivery", a collaboration with Drs. Dewhurst, Mosmann, Federoff and Bowers.

Active Research

U01 AI069511
2/1/2007 – 11/30/2014
PI: Richard C. Reichman, MD
"Units for HIV/AIDS Clinical Trials Networks"
The goals of the of the CTU are to develop a vaccine that will prevent HIV infection or delay the onset of symptomatic disease (HVTN) and to develop more effective treatments for established HIV infection in a variety of patient populations (ACTG).
Role: Co-Investigator, Director of HIV Vaccine Trials Clinical Research Site

U01 AI068614
6/29/2006 – 5/31/2013
PI: L Corey, M.D.
Subcontract to University of Rochester (via Fred Hutchinson Cancer Research Center, Seattle, WA)
Title: "HVTN Associate Director of Scientific Administration",
The major goal is to establish a Vaccine Leadership Group to direct and coordinate the HIV Vaccine Trials Network's (HVTN) work in domestic and international settings. Dr. Keefer functions in a 40% FTE capacity as a key member of the network's Core Operations Center, focused primarily on the establishment and execution of the network's scientific agenda for Phase I/II studies.
Role: PI of Subcontract at Rochester

P01 AI056356, HIV Vaccine Research and Design
Title: "HSV-1 Amplicon Vectors for HIV Vaccine Delivery"
PI: MC Keefer, M.D.
1/1/2003 – 12/31/2008
The overall goal of this Program Project is to develop an HIV vaccine strategy based on the HSV-1 amplicon vector, and to test this approach in small and large animal models. The HSV amplicon vector will be tested alone and in combination with a DNA vaccine provided by the NIAID Vaccine Research Center. The proposal includes 3 projects (immunogenicity in mice/guinea pigs; immunogenicity/protection in macaques; enhancement of amplicon technology) and 3 cores (administrative; immunologic; vector production).

P30 AI-078498, Center for AIDS Research (CFAR) program
Title: "University of Rochester Developmental Center for AIDS Research (D-CFAR)"
PI: S Dewhurst, Ph.D.
5/1/2008 – 4/30/2013
The primary mission of the University of Rochester D-CFAR is to raise the overall quality and quantity of HIV/AIDS research at the UR. This objective will be achieved by the establishment of four interconnected core facilities (Administrative Core, Developmental Core, Clinical Science Core and Basic Science Core) that synergize with the UR Clinical and Translational Science Institute to provide new opportunities for collaboration among establish investigators and those who are new to the field. Major goals are to augment the availability of biostatistical and data management services, to increase the use of mathematical modeling in HIV/AIDS research and to establish new collaborations between UR investigators and colleagues at the University of Witwatersrand and University of Cape Town in South Africa.
Role: Co-PI of D-CFAR, Director of 'Clinical Sciences Core', and Leader of 'International Collaboration Committee'.




    MD | Wright State University Boonshoft School of Medicine

    Post-doctoral Training & Residency

    07/01/1987 - 06/30/1990
    Fellowship in Infectious Disease at University of Rochester School of Medicine GME

    07/01/1986 - 06/30/1987
    Fellowship at Cincinnati Children's Hospital Medical Center

    07/01/1984 - 06/30/1986
    Residency in Internal Medicine at Christ Hospital

    07/01/1983 - 06/30/1984
    Internship in Internal Medicine at Christ Hospital

    VIEW ALL expand_more


    Patent Title: Broadly Neutralizing Anti-Influenza Monoclonal Antibody and Uses Thereof
    Patent #: 11,168,129
    Issue Date: Nov 09, 2021
    Country: United States
    Invented By: Michael C Keefer, James J Kobie, Luis Martinez-Sobrido, Aitor Nogales-Gonzalez, Michael Piepenbrink


    Journal Articles

    Stieh DJ, Barouch DH, Comeaux C, Sarnecki M, Stephenson KE, Walsh SR, Sawant S, Heptinstall J, Tomaras GD, Kublin JG, McElrath MJ, Cohen KW, De Rosa SC, Alter G, Ferrari G, Montefiori D, Mann P, Nijs S, Callewaert K, Goepfert PA, Edupuganti S, Karita E, Seaman MS, Corey L, Baden LR, Pau MG, Schuitemaker H, Tomaka F, . "Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study." The Journal of infectious diseases.. 2023 Apr 18; 227(8):939-950.

    Basu M, Fucile C, Piepenbrink M, Bunce C, Man LX, Liesveld J, Rosenberg A, Keefer M, Kobie JJ. "Mixed Origins: HIV gp120-specific memory develops from pre-existing memory and naïve B cells following vaccination in humans." AIDS research and human retroviruses.. 2023 Feb 10; Epub 2023 Feb 10.

    Mena Lora AJ, Long JE, Huang Y, Baden LR, El Sahly HM, Follmann D, Goepfert P, Gray G, Grinsztejn B, Kotloff K, Rouphael N, Sobieszczyk M, Walsh SR, Andriesen J, Shah KA, Zhang Y, Gilbert P, Janes H, Gay CL, Falsey AR, Tripp RL, Gorman RL, Tong T, Marovich M, Neuzil K, Corey L, Kublin JG, . "Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials." JAMA network open.. 2023 Jan 3; 6(1):e2251974. Epub 2023 Jan 03.